Anterior Thoracic Perforating Artery (PATA); Systematization and Applications in Reconstructive Surgery of the Head and Neck
Launched by RAMSAY GÉNÉRALE DE SANTÉ · Nov 14, 2023
Trial Information
Current as of November 09, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new option for reconstructive surgery in patients with cancers of the upper aero-digestive tract, which includes areas like the mouth and throat. Researchers are looking at a specific technique that uses a flap of skin, called the anterior thoracic perforating artery (PATA) flap, to help rebuild the affected areas after surgery. This flap can be larger than some existing options, making it potentially more suitable for extensive reconstructions. The goal is to understand how to use this flap effectively and the variations in the artery that might affect its use for different patients.
To participate in this trial, individuals must be at least 18 years old and scheduled for a Doppler ultrasound of the neck area for any medical reason. However, people with previous neck surgeries, certain neck shapes, or those who cannot provide consent cannot join. Participants will undergo assessments to determine if the PATA flap is a good fit for them and will help researchers learn more about this promising surgical option. This study is currently recruiting participants and aims to improve reconstructive surgery techniques for better patient outcomes.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patient, man or woman over 18 years old,
- • Patient admitted for an indication for Doppler ultrasound of the supra-aortic trunks (previously prescribed for any medical reason),
- • Patient having received written information and collection of the non-opposition of the patient to participate in the study,
- • Patient affiliated or beneficiary of a security regime social.
- Exclusion Criteria:
- • Minor patient,
- • History of cervical surgery,
- • Patients who have an inaccessible morphology to an exploration of the lower lateral cervical region, high, below and above the right and left clavicle such as the small necks, and/or with dermato-sclerosis,
- • Patients who do not have the intellectual or physical allowing them to give their consent,
- • Patient in period of exclusion due to another research still in progress at the time of inclusion,
- • Refusal to participate in the patient's study,
- • Protected patient: adult under guardianship, curatorship or other legal protection, deprived of liberty by judicial decision or administrative,
- • Pregnant, breastfeeding or parturient woman,
- • Patient hospitalized without consent.
About Ramsay Générale De Santé
Ramsay Générale de Santé is a leading private healthcare provider in France, dedicated to delivering high-quality medical services and advancing healthcare through innovative clinical research. With a robust portfolio of hospitals and clinics, the organization focuses on improving patient outcomes by conducting rigorous clinical trials across various therapeutic areas. Committed to enhancing healthcare solutions, Ramsay Générale de Santé collaborates with healthcare professionals, researchers, and pharmaceutical companies to facilitate groundbreaking studies that contribute to medical knowledge and patient care advancements. Their emphasis on patient safety, ethical standards, and scientific integrity underscores their role as a trusted sponsor in the clinical research landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Lyon, France
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported